CRISPR gene-editing treatment almost 100% effective after three years

The first human trial of CRISPR gene-editing technology in the United States has all but cured 31 patients of SCD and 44 of TDT.

1 minute & 22 seconds read time

The United States' first human trial of CRISPR gene-editing technology has been ongoing since 2019.

CRISPR gene-editing treatment almost 100% effective after three years 01

The trial sought to treat two rare blood diseases, beta-thalassemia and sickle cell disease (SCD). CRISPR was used to make a single genetic change to stem cells harvested from a patient's blood, designed to lead to higher fetal hemoglobin levels in red blood cells, before re-administering the stem cells to the patient.

The treatment effectively cured the first two patients to receive it in a matter of months, and follow-up results from about two years in showed completely successful treatments in 22 patients. Seven of those 22 patients were a year past their first treatment, which was still proving effective.

Three years into the trial, a new follow-up looking at 75 patients treated with the CRISPR approach has shown all but two were cured of their diseases. Forty-four had transfusion-dependent beta-thalassemia (TDT), with 42 no longer requiring blood transfusions, and the two who did had 75% and 89% reductions in the volumes of blood transfusion, respectively. All 31 patients with SCD were free of any symptoms at this follow-up stage.

"These robust data from 75 patients, of which 33 have one year or more of follow-up after exa-cel infusion, further demonstrate the potential of this investigational therapy as a one-time functional cure for patients with transfusion-dependent beta thalassemia or severe sickle cell disease," said Chief Medical Officer Carmen Bozic, from Vertex, the biotech company developing the treatment.

"I have seen first-hand the impact that this investigational therapy has had on patients in these clinical trials and continue to be impressed by the totality of the data. Given the urgency for highly effective and curative therapies for patients with hemoglobinopathies, I am excited to be part of the team working towards the goal of addressing this unmet need," said Franco Locatelli, M.D., Ph.D., Professor of Pediatrics at the Sapienza University of Rome, Director of the Department of Pediatric Hematology and Oncology at Bambino Gesu Children's Hospital.

Buy at Amazon

CRISPR: A Powerful Way to Change DNA

TodayYesterday7 days ago30 days ago
* Prices last scanned on 7/23/2024 at 7:11 pm CDT - prices may not be accurate, click links above for the latest price. We may earn an affiliate commission.

Adam grew up watching his dad play Turok 2 and Age of Empires on a PC in his computer room, and learned a love for video games through him. Adam was always working with computers, which helped build his natural affinity for working with them, leading to him building his own at 14, after taking apart and tinkering with other old computers and tech lying around. Adam has always been very interested in STEM subjects, and is always trying to learn more about the world and the way it works.

Newsletter Subscription

Related Tags